By Karen Roman Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, reported it has opened a new cutting-edge laboratory space in Cambridge, U.K. This new facility sits within a space of 150 acres and 2 million square feet...

By Daniella Parra Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said. PT-112 is a...

By Daniella Parra Sparrow Pharmaceuticals continues its PROST! Phase 2 clinical trial for treating polymyalgia rheumatica (PMR) with SPI-62 and prednisolone, adding a fourth cohort, they said. PMR, an autoimmune disorder common among the elderly, traditionally treated with steroids like...

By Karen E. Roman Apollomics, Inc. (Nasdaq: APLM), a biopharmaceutical company that develops medicines for difficult-to-treat cancers, said it appointed Matthew Plunkett, Ph.D., as Chief Financial Officer. Dr. Plunkett has over 25 years of strategic and financial experience within the...

By Exec Edge Editorial Staff RBC Capital analyst Shagun Singh maintained Zynex, Inc. (Nasdaq:ZYXI) with an outperform rating and raised its price target from $13 to $15. Meanwhile, HC Wainwright & Co. analyst Yi Chen maintained a buy rating and...

By Daniella Parra FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue was $144.9 million and a reclassification negatively impacted net revenues by $4.7 million. Gross margin was 67.5%, a decrease of 70 basis points and operating expenses were $83.6...

By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management. The company focuses on GLP-1 implants for obesity treatment due to their potential to improve patient outcomes, which...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting...

By Daniella Parra Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure. Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments...

By Daniella Parra Agendia said it has enrolled the first patient using MammaPrint for the Oncology De-Escalation of Breast Radiation (DEBRA) Trial, aiming to reduce breast radiation post-lumpectomy for low-risk, early-stage breast cancer. The trial aims to determine whether hormonal...